Source: The COVID-19 vaccine development landscape (nature.com)
|Moderna||mRNA-1273||LNP-encapsulated mRNA vaccine encoding S protein||Phase I (NCT04283461)|
|CanSino Biologicals||Ad5-nCoV||Adenovirus type 5 vector that expresses S protein||Phase I (NCT04313127)|
|Inovio Pharmaceuticals||INO-4800||DNA plasmid encoding S protein delivered by electroporation||Phase I (NCT04336410)|
|Shenzhen Geno-Immune Medical Institute||LV-SMENP-DC||DCs modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins; administered with antigen-specific CTLs||Phase I (NCT04276896)|
|Shenzhen Geno-Immune Medical Institute||Pathogen-specific aAPC||aAPCs modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins||Phase I (NCT04299724)|
There are dozens of other vaccine candidates in development:
Of the confirmed active vaccine candidates, 56 (72%) are being developed by private/industry developers, with the remaining 22 (28%) of projects being led by academic, public sector and other non-profit organizations. Although a number of large multinational vaccine developers (such as Janssen, Sanofi, Pfizer and GlaxoSmithKine) have engaged in COVID-19 vaccine development, many of the lead developers are small and/or inexperienced in large-scale vaccine manufacture.
Disclaimer: This information is only for educational purposes. Do not make any investment decisions based on the information in this article. Do you own due diligence.